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Abstract. The enzymatic conversion of azathioprine to 6-mercapto-
purine was detected at pH 6.5 with rat liver supernatants, although the
non-enzymatic reaction predominated at pH 7.0 and 7.5. Glutathione
S-transferase may catalize this conversion. Activities of the enzyme in
liver with both azathioprine and 1, 2-dichloro-4-nitrobenzene as substrate
decreased upon carbon tetrachloride-induced hepatic injury. These re-
sults may explain an ineffectiveness of azathioprine in patients with
severe hepatic damage.
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Azathioprine is known to be non-enzymatically degraded to 6-mercaptopu-
rine (6-MP) by sulfhydryl compounds in vitro (1). After the administration of
azathioprine in vivo, the recovery of significant amounts of 5-glutathionyl-l-
methyl-4-nitroimidazole demonstrates that reduced glutathione (GSH)-mediated
thiolysis is the major pathway for its conversion to 6-MP (2). It is not clear, how-
ever, where this conversion mainly occurs in vivo, why azathioprine is ineffective
in the treatment of patients with severe liver damage (3) and how the metabolism
of azathioprine is altered in injured liver (4). The conversion of azathioprine to
6-MP in vivo appears to be the first step in the sequence that leads to the biologi-
cally active drug (5). During the course of biochemical studies on azathioprine
metabolism in damaged liver, an enzymatic reaction converting azathioprine to
6-MP was detected in rat liver supernatants. Recently Kaplowitz has also sug-
gested similarly that the hepatic thiolysis of azathioprine mediated by GSH
might be enzymatic in vivo (6). The inactivation of azathioprine as an immuno-
suppressive agent by pretreatment with sulfhydryl compounds such as cysteine
or GSH may be due to a more rapid conversion of azathioprine into 6-MP before
azathioprine penetrates the target cells (5). The first step of azathioprine metab-
olism is therefore very important in the sense that the chemotherapeutic advan-
tages of azathioprine over 6-MP are well known (7). The purpose of this study
is to define the site for the cellular uptake of azathioprine by measuring the acute
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disappearance of GSH after the administration of the drug. The enzymatic con-
version of azathioprine to 6-MP and the role of glutathione S-transferase In
initiating azathioprine metabolism in th~ liver are also described.
MATERIALS AND METHODS
Materials. Azathioprine, 6-MP and GSH were obtained from Sigma Chemi-
cal Co., St. Louis, Mo. 1,2-Dichloro-4-nitrobenzene was purchased from Ishizu
Pharmaceutical Co., Ltd., Osaka. Bromosulfophtalein (BSP) was kindly supplied
by Daiichi-Pharmaceutical Co., Tokyo.
Animals. Male Sprague-Dawley rats weighing l80g were used throughout
the present study. Animals were starved overnight prior to the experiments.
Carbon tetrachloride (CC14) was administered by intragastric intubation in a single
dose ofO.5ml of a 20% solution in liquid paraffin per 100g body weight and given
water ad libitum until sacrifice. Rats were given sodium phenobarbital intra-
peritoneally at a dose of 8 mg/lOO g body weight daily for 3 days. Control animals
were starved overnight.
Analytical procedures. Liver supernatants in 4 volumes of 0.1 M phosphate
buffer, pH 7.4, were prepared as previously reported (8) and used as an enzyme
source. Glutathione S-transferase activity was measured by using 1mM 1,2-
dichloro-4-nitrobenzene and 4.5mM GSH as substrate at 37°C and a wavelength
of 345 nm in a final volume of l.Oml (9). The molar absorption of S-chloronitro-
phenyl glutathione used was 8500/cm (9).
A cuvette containing all the constituents of the following reaction mixture
except liver supernatant was used as a blank. The rate of increase in absorbance
at 325 nm was used as a measure of the rate of 6-MP formation, non-enzymatic
conversion of azathioprine to 6-MP being obtained from the blank (7). The reac-
tion mixtures contained 4.5 mM GSH, 0.1 mM azathioprine, 0.1 M phosphate
buffer, pH 6.5, 7.0 and 7.5, and liver supernatants as the enzyme source in a final
volume of l.0 ml, unless otherwise indicated. The reaction was initiated by
adding GSH at 37°C and read at 325 nm, where near maximal absorbance of
6-MP was obtained at a molar absorbtion of 19300/cm at pH 6.5. Twenty five pI
of liver supernatant used for assays contained about 0.03 pmole GSH, which is
negligible as compared with the concentrations of GSH added as substrate.
Under these conditions, the initial reaction rates were linear for at least lOmin or
within 0.05units change in absorbance/min. One unit of the enzyme activity was
defined as the amount that led to the formation of 1pmole of 6-MPImino Specific
activity is expressed in units of enzyme activity per mg of protein. Protein was
estimated by the method of Lowry et al. (10). GSH contents of liver and blood
were determined as reported previously (11).
RESULTS
A single intragastric administration of 500 mg/kg body weight of azathio-
prine resulted in a rapid fall of the hepatic GSH levels; GSH levels decreased to
about 50% of the control levels from 30min to 2h after the treatment and were
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Fig. 1. GSH levels in liver and blood after the administration of azathioprine
and 6-MP to rats. Azathioprine (el and 6-MP (0) were given intragastrically to
male Sprague-Dawley rats at a dose of 50 and 31 mg/IOO g body weight, respectively.
GSH contents in liver supernatants (--) and blood hemolysate (...... ) were deter-
mined at the times indicated. The average values from 2 rats are shown.
restored approximately to the control values within 12h (Fig. 1). No decrease of
GSH content in blood was observed during the first 30 min after azathioprine
administration, whereas a 20 % drop of the GSH levels in blood hemolysate was
observed from the 2nd to the 4th h after administration. On the other hand,
GSH levels both in the circulating blood and livers remained unchanged even
when an equimolar dose of 6-MP was administered. A dose of 50 mg/kg body
weight of azathioprine given intragastrically to rats resulted in no significant
change in GSH levels in liver. No significant alteration in GSH concentration of
kidney was ever found even with the dose of 500mg/kg body weight during the
experiments. Non-enzymatic formation of6-MP from azathioprine at 37°C and
at pH 6.5 to 7.5 with constant concentrations of 0.1 mM azathioprine and 4.5mM
GSH is shown in Fig. 2. At alkaline pH, the conversion is mostly non-enzymatic,
the reaction being dependent on the concentration of GSH (7). The conversion
of azathioprine to 6-MP may be enzymatic at pH 6.5, since the increasing
amounts of liver supernatants added to the assay mixture up to 25 pI produced a
linear increase of the fOfir.ation of 6-MP (Fig. 2). Since BSP has been reported
to be a competitive inhibitor for glutathione S-transferase with 1, 2-dichloro-4-
nitrobenzene as subtrate (9), inhibition of the enzymatic formation of 6-MP from
azathioprine by 0.06mM BSP was determined with 4.5mM GSH. The Km for
azathioprine was found to be O.03mM, which is much lower than the concentra-
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Fig. 2. Non-enzymatic and enzymatic conversions of azathioprine to 6-MP at
various pH values. Buffers used were 0.1 M phosphate buffer at pH 6.5, 7.0 and 7.5.
Activities of the enzymatic reaction using 25 ,£11 liver supernatant (0) were plotted
after subtracting for non-enzymatic changes. Non-enzymatic conversions (el are
determined in the absence of liver supernatants. Inset indicates the enzymatic con-
version of azathioprine to 6-MP at pH 6.5 with the various volumes of liver super-
natants.
-25 o 25
1/5 (mM rt
50
Fig. 3. A Lineweaver-Burk plot of the enzymatic conversion of azathioprine to
6-MP in the presence and absence of BSP. The concentration of BSP added was 0.06
mM. Azathioprine concentrations used as substrate are 0.1, 0.04 and 0.02 mM. Km
is estimated to be 0.03 mM.
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don of azathioprine as substrate for the assay. BSP was also found to be a com-
petitive inhibitor for the 6-MP-forming activity (Fig. 3). Increasing concentra-
tions of BSP produced a marked inhibition of the enzyme activity with azathio-
prine as substrate, but 6-MP had no such effect. Similar inhibitory effects of BSP
were observed with 1, 2 dichloro-4-nitrobenzene as substrate (Fig. 4) .
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Fig. 4. Inhibition of the enzymatic conversion of azathioprine to 6-MP by BSP.
The assay system was the complete assay mixture with azathioprine and 1, 2-dichloro-
4-nitrobenzene as substrate (See Materials and Methods). The relative enzyme activ-
ities were shown as percent.
The values of the enzymatic activity for azathioprine in liver are consistent
to those previously reported under normal conditions (6). In CCJrtreated rats,
glutathione S-transferase activities with I, 2-dichloro-4-nitrobenzene were ob-
served to decrease in the supernatant fractions from injured livers. Activities
with azathioprine as substrate were similarly found to decrease upon the treat-
ment (Table I). An addition of CCl4 in vitro gave no direct effect on the enzyme
TABLE 1. GLUTATHIONE S-TRANSFERASE ACTIVITY IN PHENOBARBITAL
AND CCL4-TREATED RAT LIVER
Treatment
Glutathione S-transferase
(No. of rats)
None (3)
Phenobarbital (3)
CC14 (4)
*, P<0.05
1,2-Dichloro-4-nitrobenzene
(mOfmg protein)
63. 6±2. 1
70.1 ±5. 8
24. 5±4. 9*
Azathioprine
1. 3±0. 1
1. 3±0. 1
0.8±0.1*
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reaction. The enzyme activity with azathioprine as substrate could be shown to
be present also in kidney and spleen, however, the activity was very low. Only
negligible activity was observed in other tissues, the distribution being quite
similar to that of glutathione S-transferase (9). Rats treated with phenobarbital
daily for 3 days showed no induction of the enzymatic reaction for azathioprine
and 1, 2-dichloro-4-nitrobenzene as substrate. These data are not consistent to
the previous observation (12), although long-term treatment with phenobarbital
was described in that report.
DISCUSSION
The disappearance of GSH seems to be a result of its covalent conjugation
with the imidazole moiety of azathioprine and can be used as an indicator for the
intracellular thiolysis of azathioprine. The marked decrease of GSH content in
liver and the moderate decrease in blood after azathioprine administration, which
seem to be in a dose-related fashion, suggest that liver and probably blood are
major sites for the metabolism of azathioprine to 6-MP.
This report also revealed the pr~sence of the enzymatic reaction converting
azathioprine to 6-MP with liver supernatants at pH 6.5. ESP is a competitive in-
hibitor of azathioprine conjugation with GSH, and the enzyme activities with
azathioprine and 1, 2-dichloro-4-nitrobenzene as substrate similarly decreased
upon CCl4 treatment. These results seem to suggest that glutathione S-transferase
catalyzes this conversion with broad substrate specificity. Kaplowitz (5) has
suggested from the data on elution in gel filtration, inhibition kinetics using
bilirubin and the organ distribution of this enzyme that the conversion of azathio-
prine to 6-MP is catalyzed by glutathione S-transferase at least in vitro. Although
drug-metabolizing enzymes depending upon cytochrome P-450 are located mainly
in liver microsomes, many other drugs are metabolized also in the liver super-
natant (13).
As both the enzyme activity converting azathioprine to 6-MP and hepatic
GSH levels are decreased in CCl4-damaged livers (11), this conversion may be
impaired under these conditions. However, in view of the small proportion of
the enzymatic conversion at physiological pH, it is not clear that this impairment
is of clinical importance. We are now measuring the blood clearance of azathio-
prine to investigate whether the impaired conversion to 6-MP could be observed
in patients with various liver diseases or not. Impaired activation of azathioprine
in liver diseases might be due to reduced hepatic uptake of azathioprine, de-
creased GSH and glutathione S-transferase levels and inhibition of this enzyme
by raised bilirubin concentrations. If the conversion of azathioprine to 6-MP in
vivo is exclusively chemical, it may be inferred that, in severe liver diseases, the
activity of hypoxanthine-guanine phosphoribosyltransferase is decreased and there
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is excessive catabolism of 6-MP or thioinosinic acid. It is also very important
in clinical pharmacology to see whether simultaneous injections of GSH to sys-
tematically azathioprine-treated patients are useful in preventing liver injury as a
side effect or increasing the intracellular levels of active azathioprine metabolites
in the target tissues, namely the immunocytes.
Further studies are needed to define the role in vivo of glutathione S-trans-
ferase in the conversion of azathioprine to 6-MP in order to answer the question
of whether the conversion in liver cells is enzymatic, non-enzymatic or both.
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